There is an epidemic of NAFLD which parallels those of obesity and diabetes. NAFLD covers a spectrum of disease from simple steatosis to non-alcoholic steatohepatitis (NASH) and various stages of fibrosis up to cirrhosis, and is also an increasingly important risk factor for primary hepatocellular carcinoma. Non-invasive fibrosis scoring systems and elastography can be used to identify those at risk of advanced fibrosis in NAFLD. These patients should be referred to a specialist. Life-style modification (weight loss, exercise) underpins the management of NAFLD. Pharmacological therapy, bariatric surgery and liver transplantations may be indicated in patients with advanced liver fibrosis.
Hannele Yki-Järvinen (Chair), Perttu Arkkila, Seija Eskelinen, Anne Juuti, Risto Lapatto, Anna Lempiäinen, Eero Mervaala, Anita Nikkola and Ursula Schwab